Company

ViferaXS

Biotechnology Research Hub, De 2 employees

Employees: 2

www.viferaxs.com LinkedIn

ViferaXS Overview

Headquarters: Hub, De
Website: www.viferaxs.com
Industry: Biotechnology Research
Employees: 2
Founded: 2022
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Oncology Hematology Peptide Cancer Vaccine Clinical Stage Immuno-oncology CLL AML Prostate Cancer F Fibrolamellar Carcinoma Rare Disease

About ViferaXS

ViferaXS is pioneering the forefront of immunotherapy with its revolutionary T cell activator platform, designed to harness the power of T cells in combating malignant diseases. By focusing on immunopeptidome-derived tumour antigens and employing an innovative adjuvant/formulation, XS15, the platform ensures precise targeting of naturally presented tumour antigens, enabling the direct killing of cancerous cells while activating and recruiting other immune components for a comprehensive response. We are interested in partnerships and funding discussions.

ViferaXS Contact Details

People in AeroLeads: 1

ViferaXS Org Chart

Sample employees and titles

Name	Title	Location	Contact
Alf Bernhardt, Md	Medical Strategy - Global Medical Affairs - Earlydevelopment - Celltherapy - Pipeline Strategy - Pharmadevelopment - Oncology and Hematology - Biotech	Muttenz, Basel-country, Switzerland	View